Back
75· Active
Health & Science1d 9h ago
Clinical data released today shows patients using Zepbound maintained an average weight reduction of approximately 25% over a three-year study period.
Indianapolis, Indiana, USA
Who
Eli Lilly and Company
What
Clinical data released today shows patients using Zepbound maintained an average weight reduction of approximately 25% over a three-year study period.
When
Mon, 08 Jun 2026 01:00:05 GMT · 1d 9h ago
Where
Indianapolis, Indiana, USA · 39.7684°N, 86.1581°W
Why
The pharmaceutical giant sought to quantify the long-term effectiveness and metabolic impact of tirzepatide in preventing weight regain.
The Frontline Impact
How this affects you
This reinforces the long-term clinical viability of GLP-1 treatments, potentially influencing insurance coverage policies and global obesity management standards.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.